КАНАКИНУМАБ В ЛЕЧЕНИИ РЕВМАТИЧЕСКИХ БОЛЕЗНЕЙ У ДЕТЕЙ
https://doi.org/10.15690/vsp.v13i6.1195
Аннотация
Об авторах
Е. И. АлексееваРоссия
Алексеева Екатерина Иосифовна, доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центра здоровья детей, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова
Р. В. Денисова
Россия
Список литературы
1. (Вопросы современной педиатрии. 2014; 13 (6): 9–14)
2. Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood. 1996; 87: 2095–2147.
3. Jacques C., Gosset M., Berenbaum F., Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitamin Horm. 2006; 74: 371–403.
4. Dinarello C. A. Interleukin-1b and the Autoinflammatory Diseases. New Engl. J. Med. 2009; 360: 2467–2470.
5. Simon A., van der Meer J. W. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 292: 86–98.
6. Feldmann J., Prieur A. M., Quartier P. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 2002; 71 (1): 198–203.
7. Hassink S. G., Goldsmith D. P. Neonatal onset multisystem inflammatory disease. Arthritis Rheum. 1983; 26 (5): 668–673.
8. Hawkins P. N., Lachmann H. J., Aganna E., McDermott M. F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004; 50 (2): 607–612
9. Lachmann H. J., Lowe P., Felix S. D. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 2009; 206 (5): 1029–1036.
10. Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J. B. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl J. Med. 2009; 360 (23): 2416–2425.
11. Aksentijevich I., Nowak M., Mallah M. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrinassociated autoinflammatory diseases. Arthritis Rheum. 2002; 46 (12): 3340–3348.
12. Petty R. E., Southwood T. R., Manners P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. J. Rheumatol. 2004; 31 (2): 390–392.
13. Алексеева Е. И., Шахбазян И. Е., Исаева К.Б., Афонина Е. Ю., Бзарова Т.М. Влияние особенностей течения заболевания и глюкокортикостероидной терапии на рост детей, страдающих ювенильным ревматоидным артритом. Российский педиатрический журнал. 2003; 1: 9–14.
14. Sen E. S., Ramanan A. V. New age of biological therapies in paediatric rheumatology. Arch. Dis. Child. 2014; 99 (7): 679–685.
15. Алексеева Е. И., Алексеева А. М., Валиева С. И., Бзарова Т. М., Денисова Р. В. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 2: 42–54.
16. Frosch M., Ahlmann M., Vogl T. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60 (3): 883–891.
17. Holzinger D., Frosch M., Kastrup A., Prince F. H., Otten M. H., Van Suijlekom-Smit L. W. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 2012; 71 (6): 974–980.
18. Frosch M., Vogl T., Seeliger S. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003; 48 (9): 2622–2626.
19. Gattorno M., Piccini A., Lasiglie D. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58 (5): 1505–1515.
20. de Jager W., Hoppenreijs E. P., Wulffraat N. M. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 2007; 66 (5): 589–598.
21. de Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J. Rheumatol. 1998; 25 (2): 203–207.
22. Ogilvie E. M., Khan A., Hubank M. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007; 56 (6): 1954–1965.
Рецензия
Для цитирования:
Алексеева Е.И., Денисова Р.В. КАНАКИНУМАБ В ЛЕЧЕНИИ РЕВМАТИЧЕСКИХ БОЛЕЗНЕЙ У ДЕТЕЙ. Вопросы современной педиатрии. 2014;13(6):9-14. https://doi.org/10.15690/vsp.v13i6.1195
For citation:
Alekseeva Ye.I., Denisova R.V. CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN. Current Pediatrics. 2014;13(6):9-14. (In Russ.) https://doi.org/10.15690/vsp.v13i6.1195